Stem Cell Therapy: A Promising and Prospective Approach in the Treatment of Patients With Severe Buerger's Disease

被引：13

作者：

Boda, Zoltan ^{[1
]}

Udvardy, Miklos ^{[1
]}

Razso, Katalin ^{[1
]}

Farkas, Katalin ^{[5
]}

Toth, Judit ^{[2
]}

Jambor, Laszlo ^{[2
]}

Olah, Zsolt ^{[1
]}

Ilonczai, Peter ^{[1
]}

Szarvas, Mariann ^{[1
]}

Kappelmayer, Janos ^{[3
]}

Vereb, Zoltan ^{[4
]}

Rajnavolgyi, Eva ^{[4
]}

机构：

[1] Univ Debrecen, Dept Med 2, H-4012 Debrecen, Hungary

[2] Univ Debrecen, Dept Radiol, H-4012 Debrecen, Hungary

[3] Univ Debrecen, Dept Clin Biochem & Mol Pathol, H-4012 Debrecen, Hungary

[4] Univ Debrecen, Dept Immunol, H-4012 Debrecen, Hungary

[5] St Imre Cty Hosp, Budapest, Hungary

来源：

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | 2009年 / 15卷 / 05期

关键词：

Buerger's disease; autologous bone marrow-derived stem cell therapy; therapeutic angiogenesis; nonhealing ulcer; ENDOTHELIAL PROGENITOR CELLS; CRITICAL LIMB ISCHEMIA; THROMBOANGIITIS-OBLITERANS; AUTOLOGOUS TRANSPLANTATION; LOWER-EXTREMITIES; GROWTH-FACTOR; ANGIOGENESIS; IMPLANTATION; VASCULOGENESIS; BLIND;

D O I：

10.1177/1076029608319882

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

No effective blood-flow enhancement therapies are available for patients with severe peripheral arterial disease (SPAD), thus amputation remains the only option for relief of rest pain or gangrene. Autologous bone marrow-derived stem cell therapy (ABMSCT) is an emerging modality to induce angiogenesis from endothelial progenitors. A total of 5 patients with SPAD were treated by ABMSCT using isolated CD34+ cells with characterized phenotype administered by intramuscular injections. The follow-up before and 1, 3, 6, 9, and 12 months after ABMSCT was based on clinical (rest pain, walking distance without pain, nonhealing ulcers, ankle-brachial index [ABI]) and laboratory (angiography, duplex and laser ultrasonography, TcPO2) parameters. Significant improvement of pain and walking distance was observed in all patients. Nonhealing ulcers disappeared in 3 patients and became smaller and thinner in 1 patient. The average of ABI improved significantly on the treated limb but did not change on the contralateral limb. New collaterals were detected by angiography in 3 patients, but duplex Ultrasonography detected improvement in one patient only Laser ultrasonography showed a mild significant change, TcPO2 values improved mainly on the foot. Severe adverse events were not observed. We conclude that ABMSCT with isolated CD34+ cells is safe, effective, and results in sustained clinical benefit for patients with SPAD.

引用

页码：552 / 560

页数：9

共 28 条

[1] Novel treatment of therapy-refractory limb ischemia by intra-arterial and intra-muscular transplantation of autologous adult bone marrow stem cells [J].